Pharmaxis Revenue, Profits - PXSLY Annual Income Statement

Add to My Stocks
$3.95 $0 (0%) PXSLY stock closing price Sep 18, 2018 (Closing)

Fundamental analysis of PXSLY stock involves analyzing its financial statements, apart from checking the Pharmaxis stock price. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the PXSLY stock is bound to reflect the impact of the YOY decline of -2.02%. Along with Pharmaxis assets and Pharmaxis free cash flow, Pharmaxis profits as shown in profit and loss statement give key insights about the business. The net profit for 2017 is $-13.83M and the 2017 revenue is $13.57M.

View revenue and profit details for latest and last 10 financial years.
show more
View Previous Years
View Next Years
Fiscal year is Jul - Jun2017201620152014201320122011201020092008
Pharmaxis Revenues or Net Sales
Cost Of Goods Sold (COGS)-1.4M1.45M1.7M1.17M-----
Pharmaxis Gross Profit
Research & Development Expense3.82M2.12M10.89M16.25M24.51M30.17M34.26M31M6.48M17.91M
Selling General & Admin Expense19.35M19.92M20.93M24.38M26.2M16.99M14.18M13.56M2.58M8.77M
Income Before Depreciation Depletion Amortization-10.6M-9.58M16.32M-37.72M-48.56M-46.34M-47.88M-44.1M-8.99M-26.32M
Depreciation Depletion Amortization2.3M2.2M2.85M-------
Non Operating Income-0.45M-1.98M2.02M-9.76M3.83M6.35M2.66M3.26M-8.04M
Interest Expense--1.79M--------
Pharmaxis Pretax Income
Provision for Income Taxes------0.07M----
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-13.83M-11.99M15.46M-47.58M-44.72M-39.9M-45.27M-40.88M-8.33M-18.31M
Extraordinary Items & Discontinued Operations----------
Pharmaxis Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS21.09M21.14M20.93M20.6M20.59M18.14M15.09M14.72M12.53M13.03M
Average Shares used to compute Basic EPS21.09M21.13M20.73M20.6M20.59M18.14M15.09M14.72M12.53M13.03M
Income Before Nonrecurring Items-13.83M-11.99M15.46M-39.51M-42.99M-39.91M-45.26M-40.89M-26.31M-19.54M
Income from Nonrecurring Items----8.07M-1.74M-----
Pharmaxis Earnings Per Share Basic Net
Pharmaxis Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.66-0.570.74-1.92-2.09-2.20-3.00-2.78-2.10-1.50
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Before investing one should read a report on Pharmaxis stock analysis. It helps to look at the following income statement items:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $13.57M for this year of 2017. Our Pharmaxis revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. PXSLY stock had a poor bottom line growth.

The income statement is also called statement of revenue and expense. The PXSLY financials along with Pharmaxis historical stock prices provide a lot of details about the firm.

Pharmaxis Income Statement - Key Financial Ratios